Elixinol wins A$835k arbitration ruling in stoush with German operator by Steve Jones February 14, 2023April 30, 2024 German CBD company CannaCare has been ordered to pay Elixinol Wellness more than A$800,000 following the […]
Vitura Health reports record half as CanView continues to thrive by Martin Lane February 13, 2023February 13, 2023
Shelf-life claims on TGA radar as industry warned of widespread consequences by Steve Jones February 9, 2023February 9, 2023
Legalise Cannabis Victoria introduces drug-driving bill to parliament by Martin Lane February 8, 2023March 1, 2023
Asterion’s Australian vision in tatters as firm goes into liquidation by Steve Jones February 8, 2023February 8, 2023
Queensland firm ditches cultivation plans as money runs dry by Steve Jones February 8, 2023February 8, 2023
Concerns mount over non-GMP dump in local market as reform date nears by Steve Jones February 2, 2023February 3, 2023
Second trial flagged by Ecofibre in bid to get S3 product over the line by Steve Jones February 1, 2023February 1, 2023
Company news: Althea; Cann Group; Emyria; Neurotech; Bod Science; Elixinol; Creso Pharma; MGC Pharma by Steve Jones and Martin Lane January 31, 2023February 2, 2023
Ecofibre becomes second company to confirm disappointing sleep trial results by Steve Jones January 30, 2023March 13, 2023
